• News
  • SAN DIEGO
  • BioTech

Isis Pharma posts bigger 4Q loss as costs rise

Isis Pharmaceuticals Inc. on Wednesday posted a larger loss in the fourth quarter, as it continued developing drug candidates like Kynamro, an experimental treatment for a genetic condition that causes very high cholesterol.

Isis (Nasdaq: ISIS) lost $20 million, or 20 cents per share, compared with $14 million, or 14 cents per share, in the fourth quarter of 2010. Research and development costs climbed 20 percent to $47.2 million. Revenue rose 23 percent, to $32.4 million from $26.4 million. Most of Isis' revenue comes from research and development partnerships.

Analysts expected the company to report a loss of 18 cents per share and $29.5 million in revenue, according to FactSet.

Isis shares rose50 cents, or 5.8 percent, to close at $9.11.

Isis said its revenue grew because it received a $5 million payment from partner GlaxoSmithKline PLC (NYSE: GSK) after GlaxoSmithKline chose a drug candidate as part of a collaboration between the companies. Isis also got $5.8 million from Sanofi, its partner on Kynamro.

Kynamro is designed to treat homozygous familial hypercholesterolemia, a rare genetic condition that causes severely elevated levels of “bad” LDL cholesterol. Sanofi's Genzyme unit asked European Union regulators to approve the drug in July. Isis said Wednesday that the companies will file for U.S. approval of the drug in the first quarter, and they hope to begin selling Kynamro during the second half of the year.

Isis lost $84.8 million, or 85 cents per share, in 2011. It reported a loss of $61.3 million, or 62 cents per share, in 2010. Revenue fell 9 percent, to $99.1 million from $108.5 million.

The company expects more revenue in 2012, including a total of $50 million in payments related to the marketing application and approval of Kynamro. Isis recently received a $29 million payment from new partner Biogen Idec Inc. (Nasdaq: BIIB). Isis and Biogen announced in January that they would develop a treatment for spinal muscular atrophy, a rare genetic disorder. Isis could ultimately get another $270 million from the partnership, as well as royalties on sales if the drug is approved.

Analysts expect the company to report $141.9 million in revenue this year.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
44.62
  0.68  
+ 1.55%
1,703,078,000
77.8
37.38

Insider Trade Data

Date Insider Shares Type Value
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
07/06/2015 Crooke, Stanley T 12,350 Sell $707,457

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chairman, Chief Executive Officer, Founder, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
Subscribe Today!